Miragen Therapeutics, Inc. Stock News

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor's Xtend™ half-life extension technology

Miragen has had years of disappointing share price performance with a cumulative loss of more than 90%. This is a reflection of the poor results in the two drug candidates that until recently composed

BOULDER, Colo., Nov. 10, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biotechnology company advancing new treatments for patients with diseases that are underserved by current

It was thrilling to watch MGEN stock spike, and the bull move might not be over as Miragen's new acquisition puts high-need medicine in focus. The post Value-Added Acquisition Clears the Runway for Mi

Miragen Therapeutics news of its acquisition of Viridian Therapeutics has MGEN stock skyrocketing on Wednesday. The post Miragen Therapeutics News: Why MGEN Stock Is Skyrocketing Today appeared first

Acquisition includes clinical stage anti-IGF - 1R monoclonal antibody, VRDN-001 , intended for the treatment of thyroid eye disease (TED)

After Brookline Capital Markets and Wedbush gave Miragen Therapeutics (NASDAQ: MGEN) a Buy rating last month, the company received another

After Brookline Capital Markets and Wedbush gave Miragen Therapeutics (NASDAQ: MGEN) a Buy rating last month, the company received another

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 29.41% and -74.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

* Progress on next generation microRNA-29 mimic for use in pulmonary fibrosis (MRG-229) includes new preclinical data; additional NIH grant funding triggered * Exploratory preclinical safety and phar

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...

BOULDER, Colo., Aug. 04, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapi

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FRANKFURT, Germany and BOULDER, Colo., July 28, 2020 (GLOBE NEWSWIRE) -- Goethe University, University Hospital Frankfurt and miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceuti